Bank of America’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-25,721
| Closed | -$40.9K | – | 7492 |
|
|
2024
Q1 | $40.9K | Sell |
25,721
-31,241
| -55% | -$49.7K | ﹤0.01% | 5708 |
|
|
2023
Q4 | $48.9K | Sell |
56,962
-54,543
| -49% | -$46.9K | ﹤0.01% | 5670 |
|
|
2023
Q3 | $119K | Buy |
111,505
+1,652
| +2% | +$1.77K | ﹤0.01% | 5301 |
|
|
2023
Q2 | $285K | Buy |
109,853
+25,817
| +31% | +$66.9K | ﹤0.01% | 4795 |
|
|
2023
Q1 | $343K | Buy |
84,036
+29,529
| +54% | +$120K | ﹤0.01% | 4855 |
|
|
2022
Q4 | $274K | Buy |
54,507
+13,773
| +34% | +$69.1K | ﹤0.01% | 5033 |
|
|
2022
Q3 | $533K | Sell |
40,734
-100,148
| -71% | -$1.31M | ﹤0.01% | 4610 |
|
|
2022
Q2 | $1.81M | Buy |
140,882
+100,100
| +245% | +$1.28M | ﹤0.01% | 3795 |
|
|
2022
Q1 | $622K | Sell |
40,782
-5,204
| -11% | -$79.4K | ﹤0.01% | 4968 |
|
|
2021
Q4 | $814K | Buy |
45,986
+12,961
| +39% | +$229K | ﹤0.01% | 4737 |
|
|
2021
Q3 | $695K | Buy |
33,025
+20,283
| +159% | +$427K | ﹤0.01% | 4617 |
|
|
2021
Q2 | $251K | Buy |
12,742
+5,619
| +79% | +$111K | ﹤0.01% | 5184 |
|
|
2021
Q1 | $207K | Buy |
7,123
+797
| +13% | +$23.2K | ﹤0.01% | 5364 |
|
|
2020
Q4 | $191K | Sell |
6,326
-64,235
| -91% | -$1.94M | ﹤0.01% | 4914 |
|
|
2020
Q3 | $1.12M | Buy |
70,561
+56,608
| +406% | +$901K | ﹤0.01% | 3627 |
|
|
2020
Q2 | $275K | Buy |
13,953
+8,058
| +137% | +$159K | ﹤0.01% | 4503 |
|
|
2020
Q1 | $73K | Sell |
5,895
-9,866
| -63% | -$122K | ﹤0.01% | 5108 |
|
|
2019
Q4 | $291K | Buy |
15,761
+13,832
| +717% | +$255K | ﹤0.01% | 4627 |
|
|
2019
Q3 | $27K | Buy |
1,929
+594
| +44% | +$8.31K | ﹤0.01% | 5683 |
|
|
2019
Q2 | $20K | Buy |
+1,335
| New | +$20K | ﹤0.01% | 5786 |
|